ASGCT 2026: Calidi Bio's RedTail Platform to Present
Calidi Biotherapeutics (NYSE: CLDI) will present preclinical data on its RedTail platform (CLD-401) at the ASGCT 2026 Annual Meeting, highlighting its systemic virotherapy approach for targeted tumor delivery and immune evasion, supporting a planned IND filing by the end of 2026.
Key Takeaways
- Calidi Biotherapeutics (NYSE: CLDI) will present preclinical data on its RedTail platform (CLD-401) at the ASGCT 2026 Annual Meeting.
- The RedTail platform leverages systemic virotherapy for targeted tumor delivery and enhanced immune evasion.
- The presentation supports Calidi's planned IND filing for the RedTail platform by the end of 2026.
Calidi Biotherapeutics (NYSE: CLDI) is set to present preclinical data on its RedTail platform, with lead candidate CLD-401, at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11-15, 2026, in Boston, MA. The presentation will highlight the platform's systemic virotherapy approach for targeted tumor delivery and immune evasion.
The ASGCT Annual Meeting is a key event for researchers and companies in the gene and cell therapy field. It provides a forum to share the latest scientific advancements, technological developments, and clinical trial results. Calidi's presentation is anticipated to draw attention to its innovative RedTail platform and its potential in cancer therapy.
Calidi Biotherapeutics' RedTail Platform Presentation
The speaker presentation, scheduled for May 14, 2026, will focus on preclinical data supporting the RedTail platform. The RedTail platform, spearheaded by CLD-401, is engineered to express an IL-15 superagonist, enhancing its therapeutic potential. Key aspects of the platform include its ability to achieve high intratumoral payload expression.
RedTail Platform Technology
The RedTail platform employs systemic virotherapy to achieve targeted tumor delivery. Its enGeneIC EDV (EEV) design facilitates immune evasion, potentially improving the therapeutic efficacy. The data presented at ASGCT 2026 is intended to support an Investigational New Drug (IND) filing by Calidi Biotherapeutics by the end of 2026.
Market & Investor Implications
Calidi Biotherapeutics' presentation at ASGCT 2026 is a significant step toward advancing its RedTail platform. Positive preclinical data could strengthen investor confidence and potentially attract partnerships for further development and commercialization.
What to Watch Next
The next key milestones for the RedTail platform include the IND filing with regulatory agencies and the initiation of clinical trials to evaluate its safety and efficacy in humans. Further updates from Calidi Biotherapeutics are expected as the program progresses.
Frequently Asked Questions
-
What is the RedTail platform?
The RedTail platform is a systemic virotherapy approach developed by Calidi Biotherapeutics for targeted tumor delivery and immune evasion.
-
What is CLD-401?
CLD-401 is the lead candidate from the RedTail platform, designed to express an IL-15 superagonist to enhance its therapeutic effect.
-
When and where is the ASGCT 2026 Annual Meeting?
The ASGCT 2026 Annual Meeting will be held May 11-15, 2026, in Boston, MA.
-
What is Calidi Biotherapeutics' plan for the RedTail platform?
Calidi plans to file an IND for the RedTail platform by the end of 2026, supported by the preclinical data presented at ASGCT 2026.
